Cargando…
Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report
BACKGROUND: New mutational detection techniques like next-generation sequencing have resulted in an increased number of cases with uncommon mutation and compound mutations [3%–14% of all epidermal growth factor receptor (EGFR) mutations]. In rare exon 18 mutations (3%–6%), G719X and E709X represent...
Autores principales: | Wang, Pascal, Fabre, Emmanuelle, Martin, Antoine, Chouahnia, Kader, Benabadji, Ambre, Matton, Lise, Duchemann, Boris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358716/ https://www.ncbi.nlm.nih.gov/pubmed/35957870 http://dx.doi.org/10.3389/fonc.2022.918855 |
Ejemplares similares
-
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
por: Chelabi, Samy, et al.
Publicado: (2021) -
Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy
por: Grambow-Velilla, Julia, et al.
Publicado: (2023) -
Missense Mutations in Exons 18–24 of EGFR in Hepatocellular Carcinoma Tissues
por: Panvichian, Ravat, et al.
Publicado: (2015) -
HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021) -
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
por: Goldfarb, Lucas, et al.
Publicado: (2019)